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Objectives: To investigate mechanisms of reduced susceptibility to commonly used antibiotics in Prevotella
cultured from patients with cystic fibrosis (CF), patients with invasive infection and healthy control subjects
and to determine whether genotype can be used to predict phenotypic resistance.
Methods: The susceptibility of 157 Prevotella isolates to seven antibiotics was compared, with detection of resist-
ance genes (cfxA-type gene, ermF and tetQ), mutations within the CfxA-type b-lactamase and expression of
efflux pumps.
Results: Prevotella isolates positive for a cfxA-type gene had higher MICs of amoxicillin and ceftazidime compared
with isolates negative for this gene (P,0.001). A mutation within the CfxA-type b-lactamase (Y239D) was
associated with ceftazidime resistance (P¼0.011). The UK CF isolates were 5.3-fold, 2.7-fold and 5.7-fold
more likely to harbour ermF compared with the US CF, UK invasive and UK healthy control isolates, respectively.
Higher concentrations of azithromycin (P,0.001) and clindamycin (P,0.001) were also required to inhibit the
growth of the ermF-positive isolates compared with ermF-negative isolates. Furthermore, tetQ-positive
Prevotella isolates had higher MICs of tetracycline (P¼0.001) and doxycycline (P,0.001) compared with tetQ-
negative isolates. Prevotella spp. were also shown, for the first time, to express resistance nodulation division
(RND)-type efflux pumps.
Conclusions: This study has demonstrated that Prevotella isolated from various sources harbour a common pool
of resistance genes and possess RND-type efflux pumps, which may contribute to tetracycline resistance. The
findings indicate that antibiotic resistance is common in Prevotella spp., but the genotypic traits investigated
do not reflect phenotypic antibiotic resistance in every instance.
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Introduction
Prevotella spp. are opportunistic Gram-negative obligate anaer-
obic pathogens that are associated with polymicrobial infections
in a multitude of sites throughout the body, including the respira-
tory tract.1 Although the role of these bacteria in the pathogenesis
of chronic pulmonary infection is unclear, this genus has been
repeatedly detected as a member of the respiratory microbiota
in patients with cystic fibrosis (CF), chronic obstructive pulmonary
disease (COPD) or bronchiectasis using both culture and molecu-
lar methods.2 – 9 Antibiotics routinely used in the management
of these chronic lung infections such as b-lactam, macrolide/
lincosamide/streptogramin B (MLS) and tetracycline antibiotics
have activity against these anaerobic bacteria. However, a recent
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study by our group detected resistance to antibiotics in each of
these classes among Prevotella spp. from a range of sources.10
Antimicrobial susceptibility testing of Prevotella spp. takes sev-
eral days to complete and the delay in reporting the susceptibility
results may have negative clinical implications for the patient.
Therefore, it is essential to better understand the mechanisms
underlying resistance in Prevotella isolates and to determine
whether the genotype can be used to predict phenotypic resist-
ance in this genus. These data may enable clinicians to more
rapidly select the most appropriate antibiotic if Prevotella spp.
are to be treated as part of a polymicrobial infection such as
that present in chronic pulmonary disease.
Three putative antibiotic resistance genes have been previously
detected in Prevotella spp. cultured from non-CF patients: (i) a
cfxA-type gene encoding a b-lactamase, which hydrolyses the
b-lactam bond in some penicillin and cephalosporin antibiotics;
(ii) ermF, encoding a methylase, which alters the binding site of
MLS antibiotics; and (iii) tetQ, encoding a ribosomal protection
protein, which prevents the action of tetracyclines.11,12 It is also
recognized that mutations within b-lactamase-encoding genes
may extend the enzyme’s spectrum of activity;13 however, it
has not yet been determined whether similar mutations exist
within CfxA-type b-lactamases in Prevotella spp. Furthermore,
bacterial efflux may contribute to resistance to multiple struc-
turally diverse antimicrobial agents.14 Efflux pumps associated
with clinically significant resistance in Gram-negative bacteria,
including Pseudomonas aeruginosa and Bacteroides fragilis, belong
to the resistance nodulation division (RND) family.14,15 The type of
efflux pump expressed by Prevotella spp. is currently unknown.
In this study we investigated mechanisms of resistance to
b-lactam, MLS and tetracycline antibiotics in a large number
of clinical Prevotella isolates, including for the first time CF-
associated Prevotella. We also determined whether the detection
of specific genes, mutations within a b-lactamase-encoding gene




The Prevotella isolates (n¼157) analysed in this study have been previ-
ously described in detail.10 Briefly, the isolates were split into four
groups depending on their source (UK CF, n¼57; US CF, n¼23; UK in-
vasive, n¼50; and UK healthy controls, n¼27). The CF isolates were
cultured from adult (≥18 years) CF patients attending the adult CF clinic,
Belfast, UK (sputum, n¼53; and plaque, n¼4) or paediatric (,18 years)
CF patients attending the CF clinic, University of North Carolina at Chapel
Hill, USA (sputum, n¼9; and bronchoalveolar lavage, n¼14). The UK
invasive isolates were cultured from non-CF patients (of unknown age)
with various infections including brain abscesses, kidney ulcers and
infections identified on blood culture (n¼50) and were kindly provided
Dr Valerie Hall, Anaerobe Reference Laboratory, Cardiff, UK. The remain-
ing isolates were from UK adult (≥18 years) healthy control subjects
(induced sputum, n¼27). Isolates were identified by 16S rRNA sequen-
cing (Table S1, available as Supplementary data at JAC Online). Where
available, information was obtained on azithromycin prescription (cur-
rently prescribed or not currently prescribed) at the time of sample
collection.
Table 1. Primers used for PCR, qRT-PCR and sequencing experiments




cfxA-type gene AGCTGCTATCCTATCTACACC, CCACACTCATTCCTCGTTC 214 this study
ermF CGGGTCAGCACTTTACTATTG, GGACCTACCTCATAGACAAG 466 16
tetQ CATGGATCAGCAATGTTCAATATCGG, CCTGGATCCACAATGTATTCAGAGCGG 460 17
Amplification and sequencing of the full-length cfxA-type gene
cfxA-type gene GAAAAAAACAGAAAAAAACAAATC, TTAAGATTTTACTGAAGTTTG 966 11




Species-specific efflux pumps (PCR and/or qRT-PCR)
P. melaninogenica pump 1 (PCR and qRT-PCR) GGTGGTAGCGGTCAGATTGT, TCGCCCATTTTAAGACCACT 200 this study
P. melaninogenica pump 2 (PCR and qRT-PCR) CATCCAGAACGCTTTTCACA, TGTTGGCATTGCTAAAGACG 151 this study
P. salivae pump 1 (PCR) CTCCTTGGCTGACGCTAAAG, GACTTATCAGGCAGCCGTTC 211 this study
P. salivae pump 2 (PCR) CTTTTCCGCATTTCGATTGT, CATTGAGCTTCGCTTTAGCC 157 this study
P. salivae pump 1 (qRT-PCR) TCCCATCATTCTGTGGGTTT, ATCCCGAACGCATATTGAAG 186 this study
P. salivae pump 2 (qRT-PCR) ACAGGCCACGTATGAAGAGG, TCATGCACTTTCTGCACTCC 174 this study
P. histicola pump 1 (PCR and qRT-PCR) GGCTCAAGCAAAGGCTAATG, CTTGTCGAACACCTGCTTCA 248 this study
P. histicola pump 2 (PCR and qRT-PCR) TAAGGGAAAGACGCTTGTGC, TTGTTGGTGCTGACGAAGAG 192 this study
P. nigrescens pump 1 (PCR and qRT-PCR) GCCCTAAACTCTGCACAAGC, CCTGAATGGGCAGTTTGAAT 179 this study
P. denticola pump 1 (PCR and qRT-PCR) GATTACCGTAGACCCGCAGA, TTTCTCCGATTTCCTGATGG 166 this study
16S rRNA reference gene (qRT-PCR) TAAGCATCCCACCTGGGGAG, GCTGACGACAACCATGCAGC 197 this study




Genomic DNA extraction was performed using a ZR Fecal DNA KitTM
(Zymo Research, Cambridge Biosciences, UK) in accordance with the
manufacturer’s instructions. Primer pairs for PCR assays are described
elsewhere11,16,17 or were designed in Primer3 software (Table 1) and
were purchased from Eurofins MWG Operon, UK. Each PCR was performed
using the JumpStartTM Taq DNA Polymerase Kit with 10× reaction buffer
without MgCl2 (Sigma-Aldrich, UK). The final reaction mixture (50 mL)
contained 1× PCR buffer, 200 mM of each dNTP, 0.5 mM of each forward
and reverse primer and 1.25 U of Taq polymerase. MgCl2 was added at
the concentration specified in Table S2 (available as Supplementary data
at JAC Online). DNA template (5 mL) was added and sterile DEPC-treated
water (Ambionw, UK) was used to bring the reaction volume to 50 mL.
Sterile DEPC-treated water (Ambionw, UK) replacing bacterial DNA was
used in all PCR assays as a negative control. PCR was performed using a
Veritiw Thermal Cycler (Applied Biosystems, UK). Table S2 provides details
of the cycling parameters used. Amplicons were analysed by agarose gel
electrophoresis and the resulting bands were visualized by UV lumines-
cence (Gel DocTM, Bio-Rad, UK) using Quantity One software (Bio-Rad).
Detection of antibiotic resistance genes
PCR screening assays were used for detection of the cfxA-type gene
(penicillin and cephalosporin resistance), ermF (MLS resistance) and tetQ
(tetracycline resistance). Prevotella pallens NCTC 13042 (cfxA2 and tetQ)
and Prevotella bivia R24779 (ermF) were used as positive controls. Where
available, MIC and susceptibility category (provided that anaerobic break-
points were approved by the CLSI) of a range of antibiotics (amoxicillin, cef-
tazidime, co-amoxiclav, azithromycin, clindamycin, doxycycline and
tetracycline), determined previously,10 were compared in the presence
and absence of the relevant antibiotic resistance gene in the clinical isolates.
Analysis of the CfxA-type b-lactamase in clinical
Prevotella isolates
Amplification of the full-length b-lactamase-encoding gene (966 bp) was
carried out with 20 clinical isolates of Prevotella and P. pallens NCTC 13042,
which were positive for the 214 bp fragment of the cfxA-type gene. PCR
products were purified using a QIAquickw PCR Purification Kit (Qiagen,
UK) in accordance with the manufacturer’s instructions. Both strands of
DNA were sequenced by Eurofins MWG Operon using appropriate primers
(Table 1). The CfxA-type protein sequence was determined from a con-
sensus DNA sequence. The deduced protein sequences of the CfxA-
type b-lactamase from the clinical Prevotella isolates and P. pallens
NCTC 13042 were compared between isolates deposited in GenBank and
correlated with amino acid substitutions. The MICs of amoxicillin, ceftazi-
dime and co-amoxiclav determined previously10 were also compared
between isolates with amino acid substitutions within the b-lactamase
protein sequence.
Detection of species-specific RND-type efflux pumps
Protein sequences of RND efflux pumps in P. aeruginosa PAO1 (MexAB-
OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM) and B. fragilis
ATCC 25285 (BmeABC1–8) were searched for homologies within five
Prevotella genomes (Prevotella denticola F0289, Prevotella nigrescens
ATCC 33563, Prevotella melaninogenica ATCC 25845, Prevotella histicola
F0411 and Prevotella salivae DSM 15606) using protein BLAST. Species-
specific primer pairs were designed to amplify the gene encoding the linker
protein, a periplasmic membrane fusion protein,14 of the efflux pump
operon found in the Prevotella genomes (Table 1). Clinical Prevotella iso-
lates (n¼87) that belonged to these five species (P. denticola, n¼13;
P. nigrescens, n¼12; P. melaninogenica, n¼34; P. histicola, n¼20; and
P. salivae, n¼8) and two type strains (P. denticola NCTC 13067 and
P. melaninogenica ATCC 25845) were selected and screened for the pres-
ence of species-specific RND-type efflux pumps.
Transcription levels of species-specific RND-type efflux
pumps
A detailed description of the method used to prepare total RNA from
stationary growth (optical density at 550 nm of 0.8–1.3) cultures
(n¼26) is provided elsewhere.18 Clinical isolates were selected randomly.
RNA integrity was verified on a 1% agarose gel. The quantitative real-time
PCR (qRT-PCR) procedure was carried out as previously described,18 with
several modifications for use with Prevotella spp. as follows: (i) 500 ng of
total RNA was used for cDNA generation; (ii) the cycling conditions used
were 10 min at 958C followed by 40 cycles of 15 s at 958C and 60 s at
608C; and (iii) real-time PCR was performed in a final reaction volume of
20 mL containing 2.5 mL of cDNA (1 :10 dilution), 10 mL of FastStartw
Universal SYBR green master mix with ROX (Roche, UK), 0.2 mL of each for-
ward and reverse primer (10 mM) and 7.1 mL of DEPC-treated water
(Ambionw). The species-specific efflux pump primers that were used for
qRT-PCR are listed in Table 1 and were designed from the gene encoding
the linker protein of the efflux pump operon found in the Prevotella
genomes. The comparative threshold cycle (CT) method (DDCT) was used
to determine the relative transcription levels using the 16S rRNA gene as
the endogenous control. Data were analysed using Applied Biosystems
7500 software.
Inhibition of efflux pumps
Under strict anaerobic conditions clinical Prevotella isolates (n¼25) were
inoculated onto supplemented brucella blood agar with or without an
efflux pump inhibitor (EPI), Phe-Arg b-naphthylamide dihydrochloride
(Sigma-Aldrich), added uniformly to the agar at a final concentration
of 80 mg/L.19 The MICs of amoxicillin, azithromycin, ceftazidime, clinda-
mycin, co-amoxiclav, doxycycline and tetracycline were then determined
in the presence or absence of the EPI by Etestw (bioMérieux, France)
according to the manufacturer’s instructions.
Statistical analysis
MICs were compared in isolates that were positive versus negative for:
(i) the cfxA-type gene (amoxicillin, ceftazidime and co-amoxiclav);
(ii) ermF (azithromycin and clindamycin); and (iii) tetQ (tetracycline and
doxycycline) using the Mann–Whitney test. Isolates were separated into
groups depending on a Y239D substitution in the CfxA-type b-lactamase
and amoxicillin, ceftazidime and co-amoxiclav MICs compared using the
Mann–Whitney test. A relative risk (RR) analysis was performed to
determine the risk of harbouring ermF in UK CF isolates relative to US CF,
UK invasive and UK healthy control isolates. Isolates were grouped
according to patient (UK CF, US CF and healthy control) and prescription of
azithromycin (currently prescribed versus not currently prescribed) and a x2
test with Yates correction was used to determine whether there was evi-
dence of an association between ermF and current azithromycin prescrip-
tion. The Wilcoxon signed rank test was used to compare the MICs before
and after inhibition of the efflux pumps. All statistical analyses were carried
out using an SPSS software package (SPSS Version 19; Chicago, IL, USA). A
two-tailed P value ,0.05 was considered statistically significant.
Results
The cfxA-type gene was common among Prevotella
isolates from a range of sources and was associated
with high MICs of b-lactam antibiotics
The cfxA-type gene codes for a class 2e b-lactamase13 and was
detected in 70/155 (45%) isolates with similar proportions in
Sherrard et al.
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each Prevotella group positive for the gene (Figure 1). The isolates
positive for the cfxA-type gene had significantly higher MICs of
amoxicillin and ceftazidime compared with isolates negative for
the cfxA-type gene (P,0.001, Mann–Whitney test) (Figure 2).
Although this b-lactamase is typically inhibited by clavulanic
acid,13 isolates positive for the cfxA-type gene also had significantly
higher MICs of co-amoxiclav compared with isolates negative for
the cfxA-type gene (P,0.001; Figure 2). However, only 16/69
(23%) isolates positive for the cfxA-type gene were also categor-
ized as resistant or intermediately resistant to co-amoxiclav.
Prevotella isolates with a Y239D substitution in the
CfxA-type b-lactamase protein sequence were more
resistant to ceftazidime
The deduced amino acid sequences of the CfxA-type b-lactamase
in 20 clinical isolates and one type strain (P. pallens NCTC 13042)
were .98% similar. Several amino acid substitutions were
observed when compared with CfxA from Bacteroides vulgatus
(GenBank protein accession number AAB17891) (Table 2). Each
of the deduced amino acid sequences possessed the K272E
substitution common to CfxA2, and an additional substitution at
residue 239 (Y239D/C/S) was observed more than once (Table 2).
Given that the Y239D substitution was most common (Table 2;
CfxA3), the MICs of amoxicillin, ceftazidime and co-amoxiclav
were compared between isolates with this substitution (Table 2).
Those clinical isolates with an aspartic acid (D) at this residue
(n¼6) had significantly higher MICs of ceftazidime compared
with those with tyrosine (Y) at this position (n¼11) (P¼0.011,
Mann–Whitney test). No difference in the MICs of amoxicillin and
co-amoxiclav was detected between the two groups.
The UK CF isolates were more likely to harbour ermF
compared with the other groups
The ermF gene was detected most frequently in the UK CF
Prevotella isolates (44%; Figure 1). There was a significant differ-
ence in the proportion of ermF-positive isolates between the UK CF
group and the US CF (RR 5.26, 95% CI 1.35–20.49, P¼0.005), UK
invasive (RR 2.74, 95% CI 1.36–5.52, P¼0.004) and UK healthy
control (RR 5.70, CI 1.46–22.29, P¼0.003) groups. The risk of UK
CF isolates harbouring ermF was increased 5.3-fold, 2.7-fold and
5.7-fold relative to the US CF, UK invasive and UK healthy control
isolates, respectively. Significantly higher concentrations of both
azithromycin (P,0.001, Mann–Whitney test) and clindamycin
(P,0.001) were required to inhibit the ermF-positive isolates
compared with the ermF-negative isolates (Figure 2). Furthermore,
28/37 (76%) ermF-positive isolates were categorized as resistant
to clindamycin. A significant association between a current
patient prescription of azithromycin and the presence of
ermF among clinical Prevotella isolates was also detected
(x2¼31.534, P,0.001); 11/27 (41%) and 9/46 (20%) isolates
from patients currently and not currently prescribed azithromycin,







































































































Figure 1. Prevalence of resistance genes (cfxA-type gene, ermF and tetQ) in each of the Prevotella groups.
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The tetQ gene was detected in similar proportions in each
group and was associated with high MICs of tetracycline
antibiotics
Thirty-two of 151 (21%) Prevotella isolates were positive for tetQ.
This gene was detected in similar proportions in each group
(Figure 1). Significantly higher concentrations of tetracycline
(P¼0.001, Mann-Whitney test) and doxycycline (P,0.001) were
required to inhibit the growth of tetQ-positive compared with
tetQ-negative isolates (Figure 2). Among the tetQ-positive iso-
lates, 19/23 (83%) were categorized as resistant or intermediately
resistant to tetracycline.
A high percentage of Prevotella isolates tested harboured
one or more antibiotic resistance genes
Of the 151 Prevotella isolates tested for the three antibiotic
resistance genes, 93 (62%) were positive for one or more of the
antibiotic resistance genes by PCR (Figure S1, available as
Supplementary data at JAC Online). Twenty-six isolates carried
two resistance genes [cfxA-type gene and ermF, 13/26 (50%);
cfxA-type gene and tetQ, 11/26 (42%); and ermF and tetQ, 2/26
(8%)] and 6/151 (4%) isolates of Prevotella were found to harbour
all three resistance genes (Figure S1).
Prevotella spp. express RND-type efflux pumps, which
may contribute to tetracycline resistance
Genes encoding a linker protein, inner membrane protein and
outer membrane protein were detected within each of the five
Prevotella genomes searched in silico and were organized as an
operon similar to RND-type efflux pumps in other bacteria.14 At
the time of our analysis a single efflux pump was identified in
P. denticola F0289 and P. nigrescens ATCC 33563 and two
efflux pumps were detected in P. melaninogenica ATCC 25845,
P. histicola F0411 and P. salivae DSM 15606 (Table S3, available
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Figure 2. Comparison of susceptibility (MICs) in isolates positive and negative for associated resistance genes. In the box and whisker plots, the top and
bottom boundaries of each box indicate the 75th and 25th quartile values, respectively, with the line inside the box representing the median (50th
quartile). The ends of the whiskers indicate the range. Any isolates recorded as having an MIC greater than the maximum concentration (.256 mg/L)
or lower than the minimum concentration (,0.016 mg/L) on the Etestw strip are shown as double the maximum concentration or half the lower
concentration, respectively. *P,0.05 and ≥0.001; **P,0.001.
Sherrard et al.
2694
The species-specific linker genes were present in the majority
of Prevotella spp. isolates tested (83/87, 95%) by PCR. The remain-
ing isolates (P. melaninogenica) were either negative by PCR for
one (n¼2) or both (n¼2) of the predicted linker genes. The tran-
scription levels of the species-specific efflux pumps were analysed
in 25 clinical isolates and P. melaninogenica ATCC 25845 by
qRT-PCR. Twenty-one of 25 (84%) isolates and the type strain
expressed the expected linker genes (Figure S2, available as
Supplementary data at JAC Online). For the remaining four isolates
either no expression was detected (P. melaninogenica, n¼1; and
P. histicola, n¼2) or one of two expected pumps was expressed
(n¼1; Figure S2). The MICs of seven antibiotics in the presence
or absence of an EPI was also investigated. A statistically signifi-
cant decrease in the MICs of tetracycline (P¼0.001, Wilcoxon
signed rank test) was detected in the presence of the EPI, with
no statistically significant differences apparent for the remaining
antibiotics (Figure 3). A further analysis of the tetracycline MIC
data revealed that 17/25 (68%) Prevotella isolates were negative
by PCR for tetQ. A significant decrease in MICs was detected
among the tetQ-negative isolates in the presence of the EPI
(P¼0.025, Wilcoxon signed rank test). In contrast, no statistical
difference in the MIC of tetracycline was detected in the presence
or absence of an EPI for the tetQ-positive isolates (n¼8).
Discussion
Prevotella spp. have been detected in the airway microbiota in dis-
eases characterized by chronic infection, including CF, COPD and
bronchiectasis.4,6,8 Although their role in infection and inflamma-
tion in these conditions has not been clearly defined, this obligate
anaerobe may be a future target for antimicrobial treatment.
In vitro antimicrobial susceptibility testing may be used clinically
to guide the treatment of individual anaerobic isolates.
Unfortunately, in vitro susceptibility testing of Prevotella spp. can
be difficult to perform given the fastidious nature of this genus.
A genotypic prediction of resistance may be an attractive alterna-
tive to susceptibility testing with some antibiotics and has proved
useful to detect single antibiotic resistance gene targets asso-
ciated with resistance, e.g. mecA associated with methicillin
resistance in Staphylococcus aureus.20 Before genotypic prediction
can be used, it is important to understand the mechanisms
of resistance that are commonly associated with reduced suscep-
tibility in the target bacterium. Therefore, in this study we investi-
gated, in clinical Prevotella isolates, putative mechanisms of
resistance to antibiotics used in the treatment of chronic lung
infections. We also explored the relationship between the pres-
ence of specific antibiotic resistance genes, amino acid mutations
within the CfxA-type b-lactamase and the expression of efflux
pumps and in vitro antimicrobial susceptibility and determined
whether the genotype could predict phenotypic resistance.
b-Lactamase production by bacteria is a key mechanism of
resistance to b-lactam antibiotics, and the presence of a
cfxA-type gene in the Prevotella isolates in this study was asso-
ciated with high MICs of amoxicillin, as has previously been
reported for Prevotella isolates from dental infection.21 In the
current study, isolates harbouring the cfxA-type gene also had








Protein accession number of
identical sequenceamoxicillin ceftazidime co-amoxiclav
UK CF 6 2 1.5 K272E, L189F NA NA
UK CF .256 .256 64 K272E, Y239S NA NA
UK CF .256 256 .256 K272E, Y239S NA NA
UK CF .256 128 3 K272E, Y239D CfxA3 AAL79549
UK CF 32 2 12 K272E CfxA2 ADD23513
UK CF 64 4 6 K272E CfxA2 ADD23513
UK CF 64 3 12 K272E CfxA2 ADD23513
UK CF 48 .256 64 K272E, Y239D CfxA3 AAL79549
UK CF 96 .256 0.064 K272E, Y239C CfxA5 AAV37206
UK invasive .256 .256 3 K272E, Y239D CfxA3 AAL79549
UK invasive .256 4 3 K272E CfxA2 ADD23513
UK invasive .256 .256 3 K272E, Y239D CfxA3 AAL79549
UK invasive 64 1.5 0.125 K272E CfxA2 ADD23513
UK invasive 48 3 0.064 K272E, Y239D CfxA3 AAL79549
UK invasive .256 .256 0.25 K272E CfxA2 ADD23513
UK healthy control 192 32 0.25 K272E CfxA2 ADD23513
UK healthy control 3 1.5 0.25 K272E CfxA2 ADD23513
UK healthy control 4 0.25 0.032 K272E CfxA2 ADD23513
UK healthy control 2 16 0.023 K272E CfxA2 ADD23513
UK healthy control .256 .256 3 K272E, Y239D CfxA3 AAL79549
Type strain 1.5 3 0.064 K272E CfxA2 ADD23513
NA, not applicable; AAL79549, Capnocytophaga ochracea; ADD23513, Prevotella intermedia; AAV37206, Parabacteroides distasonis.
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higher MICs of ceftazidime and co-amoxiclav compared with iso-
lates negative for the gene. This is in contrast to the findings of a
previous study, which found that all Prevotella isolates positive for
the b-lactamase-encoding gene cfxA2 (n¼62) were amoxicillin
resistant, but susceptible to ceftazidime and co-amoxiclav.11
Giraud-Morin et al.11 proposed that substrate specificity may be
extended by mutations within the cfxA-type gene as it is recog-
nized that mutations in other b-lactamase-encoding genes (e.g.
TEM-type b-lactamases) widen substrate specificity.13 In the pre-
sent study, when the CfxA-type amino acid sequence was ana-
lysed, the K272E substitution, common to CfxA2, was detected
in all 20 isolates tested. However, additional substitutions at
amino acid residue 239 were also found, which are characteristic
of other CfxA2-like sequences (CfxA3 and CfxA5) suggesting that
Prevotella isolates from a range of sources produce variants of the
CfxA2 b-lactamase. Furthermore, the data indicate that a Y239D
substitution within the CfxA2-type protein sequence is associated
with significantly higher MICs of ceftazidime. Therefore, the pres-
ence of this substitution may reduce susceptibility to ceftazidime.
Resistance to MLS antibiotics in Prevotella spp. may be due to
an ermF-encoded methylase, which alters the binding site of
these antibiotics. Isolates positive for ermF were associated with
higher MICs of azithromycin and clindamycin. In agreement with
this, Xie et al.22 detected 13/19 (68%) clindamycin- and/or
roxithromycin-resistant Prevotella isolates from dental abscesses
to be positive for ermF. Furthermore, the risk of UK CF isolates
harbouring ermF was much higher compared with those collected
from other patient groups. This may reflect the fact that the UK CF
isolates were cultured from adult CF patients, where long-term
azithromycin is prescribed in a high percentage of patients com-
pared with the paediatric US CF isolates or UK invasive and healthy
control isolates, for whom the use of azithromycin is less likely.
The hypothesis of higher resistance in Prevotella being linked to
azithromycin use appears to be confirmed by the association
between a current patient prescription of azithromycin and the
presence of ermF among the Prevotella isolates. Ideally, we
would like to investigate the prevalence of ermF in Prevotella
isolates from young patients with CF from the UK in future studies.
However, as bronchoscopy is not performed in young children in
the UK as part of routine clinical practice, obtaining clinically rele-
vant respiratory samples is challenging. The expression of ermF in
these isolates could also be evaluated between CF patients trea-
ted with or without chronic azithromycin. However, this would
also be difficult to do as most CF patients are prescribed long-term
azithromycin therapy.
Between 14% and 30% of Prevotella isolates in each group
were also positive for tetQ, which has been associated with
resistance to tetracyclines, with tetQ-positive isolates having
statistically higher MICs of both doxycycline and tetracycline.
A previous study also reported that 25% of Prevotella
isolates cultured from clinical specimens and the resident
microbiota of healthy subjects were positive for tetQ.12 Similarly,
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Figure 3. Antibiotic susceptibility (MICs) of Prevotella isolates (n¼25) in the absence or presence of the EPI Phe-Arg b-naphthylamide dihydrochloride. In
the box and whisker plots, the top and bottom boundaries of each box indicate the 75th and 25th quartile values, respectively, with the line inside the box
representing the median (50th quartile). The ends of the whiskers indicate the range. Any isolates recorded as having an MIC greater than the maximum
concentration (.256 mg/L) or lower than the minimum concentration (,0.016 mg/L) on the Etestw strip are shown as double the maximum
concentration or half the lower concentration, respectively.
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Arzese et al.12 investigated tetQ and susceptibility to tetracycline,
and reported that all tetQ-positive isolates (n¼14) were resistant
to tetracycline.
The results of this study indicate that if one of the target resist-
ance genes is detected in clinical Prevotella isolates, it is more
likely that these isolates will have higher MICs of the associated
antibiotics. However, susceptible isolates with low MICs were
also positive for the target resistance gene; this suggests
that the choice of antibiotic treatment cannot be based solely
on the presence of the gene. This was particularly evident
for co-amoxiclav, where only 23% of isolates positive for the
cfxA-type gene were resistant or intermediately resistant to
co-amoxiclav. There were no amino acid mutations identified
within the CfxA-type b-lactamase that were associated with
reduced susceptibility to this antibiotic. These data suggest that
the cfxA-gene itself may not be a major mechanism of
resistance to co-amoxiclav. However, the determination of
co-amoxiclav susceptibility post-complementation of a suscep-
tible Prevotella strain with mutated cfxA genes would be required
to support this hypothesis.
We also investigated whether the expression of efflux pumps
could contribute to antibiotic resistance in Prevotella spp. The con-
stitutive expression or overexpression of efflux pumps by bacteria
is an important putative resistance mechanism as it may contrib-
ute to the reduced susceptibility to structurally dissimilar antibio-
tics. This study is the first to report the type of efflux pump in the
Prevotella genome and whether these efflux pumps were
expressed and potentially contributing to antibiotic resistance in
five different species. Although detected in higher numbers in
other bacterial genomes,14,15 a maximum of two RND-type efflux
pumps were detected within five Prevotella genomes, which were
homologous to efflux pumps found in P. aeruginosa PAO1 and
B. fragilis ATCC 25285. In P. aeruginosa, it is recognized that
MexAB-OprM and MexXY-OprM efflux systems are constitutively
active.14 In this study, 22/25 (88%) clinical Prevotella isolates
tested demonstrated pump expression. It is also known that
efflux pumps expressed by P. aeruginosa contribute to resistance
to a range of antibiotics including b-lactams and tetracycline.14 In
our study, the presence of an EPI resulted in a statistically signifi-
cant decrease in the MICs of tetracycline, suggesting that this
antibiotic is a potential substrate of Prevotella efflux pumps, espe-
cially in isolates negative for tetQ. Further work includes compar-
ing the expression levels of efflux pumps in a large number of
isolates susceptible, intermediately resistant and resistant to
tetracycline across all the different species.
A number of Prevotella isolates in this study also had high
MICs of an antibiotic, but lacked a cfxA-type gene, ermF or tetQ.
Although it is feasible that these isolates harbour a novel resist-
ance mechanism, it is also possible that the primers used in this
study did not recognize the target antibiotic resistance genes,
which could be due to mutations within the target sequence.
Furthermore, we cannot rule out that Prevotella isolates may
harbour more than one mechanism of resistance for the same
antibiotics.
There are a number of limitations to this study. Single bacterial
colonies from each clinical sample were isolated and those
identified as Prevotella spp. were subsequently used in this
study. We cannot discount that other genotypes of Prevotella
spp., which may have a different susceptibility profile from that
detected, were present in the same sample. Furthermore, the
microenvironment in chronic lung infections may induce different
metabolic conditions and affect in vivo susceptibility compared
with our in vitro results; however, the current approach to testing
susceptibility and detecting resistance genes mirrors techniques
used frequently in clinical practice.
In summary, this study has shown that Prevotella isolated from
chronic pulmonary infection, invasive infections and the healthy
respiratory tract harbour a common pool of resistance genes
and possess RND-type efflux pumps, which potentially contribute
to a reduced susceptibility to tetracycline. The presence of a
cfxA-type gene, ermF or tetQ was associated with significantly
higher MICs of b-lactam, MLS and tetracycline antibiotics, respect-
ively, and an amino acid substitution within the CfxA-type
b-lactamase was associated with higher MICs of ceftazidime.
The data suggest that the presence of these genes increases
the likelihood of resistance, but absence does not imply suscepti-
bility. There was also an association between current patient pre-
scriptions of azithromycin and the presence of ermF among the CF
Prevotella isolates, suggesting that antibiotic pressure may have
contributed to the spread of ermF among these isolates.
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